Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | BAX | Q07812 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3796451 | 0.98 | LTA4H (0.55) | LTA4HTSHRNR1H2BAXMAOA | |
| SCHEMBL28476939 | 0.92 | LTA4H (0.48) | LTA4HTSHRNR1H2BAXMAOA | |
| SCHEMBL14848539 | 0.90 | ALDH1A1 (0.41) | LTA4HTSHRNR1H2BAXMAOA | |
| Sulfuric Acid SCHEMBL5678657 | 0.88 | SOS1 (0.52) | LTA4HTSHRNR1H2BAXMAOA | |
| Sulfuric Acid SCHEMBL5678661 | 0.88 | CA1 (0.47) | LTA4HTSHRNR1H2BAXMAOA | |
| Sulfuric Acid SCHEMBL5678667 | 0.85 | SOS1 (0.49) | LTA4HTSHRNR1H2BAXCA1 | |
| SCHEMBL11871655 | 0.80 | LTA4H (0.50) | LTA4HTSHRNR1H2BAXMAOA | |
| SCHEMBL31448055 | 0.79 | SOS1 (0.44) | LTA4HTSHRSOS1MEN1KMT2A | |
| SCHEMBL31448011 | 0.79 | TEAD4 (0.52) | TSHRCA1CA2CA9MEN1 | |
| SCHEMBL122719 | 0.79 | LTA4H (0.92) | LTA4HTSHRNR1H2BAXMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475286-B1 | SUBSTITUTED PYRROLO [2, 3-D]PYRIDAZIN-4-ONES AND PYRAZOLO [3, 4-D]PYRIDAZIN-4-ONES AS PROTEIN KINASE INHIBITORS | FOCHON PHARMACEUTICALS LTD (CN) | 2025-03-26 | — | — | EP | disclosed |
| CN-118834121-A | Method for preparing biaryl compound by cross-coupling of diazonium salt and aryl bromide under nickel catalysis | 浙江工业大学 | 2024-10-25 | — | — | CN | disclosed |
| US-20220213092-A1 | BICYCLIC PYRAZOLE BRUTON'S TYROSINE KINASE INHIBITORS | ABBVIE INC (US) | 2022-07-07 | — | — | US | disclosed |
| WO-2022132997-A1 | BICYCLIC PYRAZOLE BRUTON'S TYROSINE KINASE INHIBITORS | ABBVIE INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| CN-109476666-B | Compound as kinase inhibitor | 上海复尚慧创医药研究有限公司 | 2021-10-15 | — | — | CN | disclosed |
| US-10800785-B2 | Substituted pyrrolo[2,3-d]pyridazin-4-ones and pyrazolo[3,4-d]pyridazin-4-ones as protein kinase inhibitors | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2020-10-13 | — | — | US | disclosed |
| US-20190161489-A1 | SUBSTITUTED PYRROLO [2, 3-D] PYRIDAZIN-4-ONES AND PYRAZOLO [3, 4-D] PYRIDAZIN-4-ONES AS PROTEIN KINASE INHIBITORS | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2019-05-30 | — | — | US | disclosed |
| EP-3475286-A1 | SUBSTITUTED PYRROLO [2, 3-D]PYRIDAZIN-4-ONES AND PYRAZOLO [3, 4-D]PYRIDAZIN-4-ONES AS PROTEIN KINASE INHIBITORS | Shanghai Fochon Pharmaceutical Co., Ltd. (CN) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017219955-A1 | SUBSTITUTED PYRROLO [2, 3-D] PYRIDAZIN-4-ONES AND PYRAZOLO [3, 4-D] PYRIDAZIN-4-ONES AS PROTEIN KINASE INHIBITORS | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2017-12-28 | — | — | WO | disclosed |
| CN-102089712-A | On-press developable imageable elements | EASTMAN KODAK CO | 2011-06-08 | — | — | CN | disclosed |
| US-7157205-B2 | Intermediate layer composition for multilayer resist process, pattern-forming process using the same, and laminate | FUJI PHOTO FILM CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-6844139-B2 | Method for forming a lithographic printing plate | KODAK POLYCHROME GRAPHICS, LLC | 2005-01-18 | — | — | US | disclosed |
| WO-2004063816-A1 | METHOD FOR FORMING A LITHOGRAPHIC PRINTING PLATE | KODAK POLYCHROME GRAPHICS LLC (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20040131973-A1 | Method for forming a lithographic printing plate | BANK OF AMERICA, N.A., AS AGENT | 2004-07-08 | — | — | US | disclosed |
| US-4770973-A | READABLE BY OPTICAL DEVICES AND FIXED BY LIGHT | Kanzaki Paper Manufacturing Limited (JP) | 1988-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213092-A1 | BICYCLIC PYRAZOLE BRUTON'S TYROSINE KINASE INHIBITORS | BTK, LYN, ABL1 | LTA4H 3117/4885TSHR 1578/4885NR1H2 3416/4885 |
| US-10800785-B2 | Substituted pyrrolo[2,3-d]pyridazin-4-ones and pyrazolo[3,4-d]pyridazin-4-ones as protein kinase inhibitors | BTK, TYK2, SYK | LTA4H 2312/4885TSHR 2144/4885NR1H2 4246/4885 |
| US-20190161489-A1 | SUBSTITUTED PYRROLO [2, 3-D] PYRIDAZIN-4-ONES AND PYRAZOLO [3, 4-D] PYRIDAZIN-4-ONES AS PROTEIN KINASE INHIBITORS | BTK, TYK2, SYK | LTA4H 2312/4885TSHR 2144/4885NR1H2 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.